NCT06055361View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

PHASE1RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 18, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Atopic Dermatitis
Interventions
DRUG

BxC-I17e (primed iMSC derived Extracellular vesicles(EV))

Pharmaceutical form : solution for injection

DRUG

Placebo

Pharmaceutical form : solution for injection

Trial Locations (3)

17011

RECRUITING

DermDox Centers for Dermatology, Camp Hill

19104

RECRUITING

University of Pennsylvania, Philadelphia

72117

RECRUITING

Arkansas Research Trials, North Little Rock

Sponsors

Lead Sponsor

Brexogen Inc.
All Listed Sponsors
lead

Brexogen Inc.

INDUSTRY